Use of the MAIEA Technique to Confirm the Relationship between the Cromer Antigens and Decay‐Accelerating Factor and to Assign Provisionally Antigens to the Short‐Consensus Repeats

Petty, A. C.; Daniels, Geoff; Anstee, D. J.; Tippett, Patricia

doi:10.1111/j.1423-0410.1993.tb02172.x

Cited by 25 publications

(13 citation statements)

References 19 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The technique was successful and included some preliminary results on some of the Kell antigens [17]. Another study confirmed the relationship between the Cromer system antigens and decay-accelerating factor, and also provisionally assigned antigens to the different short consensus repeats [18].…”

Section: Introductionmentioning

confidence: 84%

Application of the MAIEA Assay to the Kell Blood Group System

Petty¹,

Daniels²,

Tippett³

1994

Vox Sanguinis

Self Cite

View full text Add to dashboard Cite

The monoclonal antibody-specific immobilisation of erythrocyte antigens (MAIEA) test has been employed to investigate the Kell system using five monoclonal antibodies which recognise high frequency epitopes on the 93,000-molecular weight Kell glycoprotein: BRIC 18, BRIC 68, BRIC 107, BRIC 203 and 6-22. BRIC 107, which has anti-k-like (KEL2) specificity, identifies a distinct epitope, whilst competitive binding assays suggested that BRIC 203 (anti-Kpbc), BRIC 18, BRIC 68 and 6-22 (anti K14) comprise an overlapping set of epitopes. The MAIEA assay has been very successful in confirming the assignment of most of the Kell and para-Kell antigens to the Kell protein. Due to the competitive nature of the assay and the fact that the monoclonal antibodies bind to different regions, the results also suggest the relative positions of some of the Kell antigens on the Kell protein; these appear to be located in at least five spatially distinct regions.

show abstract

Section: Introductionmentioning

confidence: 84%

Application of the MAIEA Assay to the Kell Blood Group System

Petty¹,

Daniels²,

Tippett³

1994

Vox Sanguinis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cromer specificity was confirmed in the monoclonal antibody immobilization of erythrocyte antigens (MAIEA) assay (Petty, 1993). Positive ratios were obtained with the following murine monoclonal anti‐DAF: BRIC 230 (SCR1), BRIC 110 (SCR2) and BRIC 216 (SCR3) (Petty et al ., 1993). BRIC 216 produced lower ratios (3·2, compared to 10·7 for BRIC 230 and 5·3 for BRIC 110) suggesting that partial inhibition had occurred.…”

Section: Case Studymentioning

confidence: 99%

SERF: a new antigen in the Cromer blood group system

Banks¹,

Poole²,

Ahrens

et al. 2004

Transfusion Medicine

View full text Add to dashboard Cite

The Cromer blood group system consists of eight high incidence and three low incidence antigens carried on decay-accelerating factor (DAF). This report describes the identification and characterization of a new Cromer high incidence antigen, named SERF. Sequence analyses of DNA from a Thai female whose serum contained the alloantibody to a high incidence antigen in the Cromer blood group system (anti-SERF) and from her two children were performed. Reverse transcriptase-polymerase chain reaction (RT-PCR) and sequence analysis on cDNA from the proband and PCR-restriction fragment length polymorphism analysis on DNA from Thais were also performed. To map the epitope, DAF deletion mutants were tested by immunoblotting with anti-SERF. Sequence analysis revealed a substitution of 647C>T in exon 5 DAF in the proband. The proband's two children and two of 100 Thais were heterozygotes 647C/T. Analysis using DAF deletion mutants revealed the antigenic determinant to be within short consensus repeat 3 (SCR3), which is encoded by exon 5. This study describes a novel high incidence antigen (SERF) in the Cromer blood group system characterized by the amino acid proline at position 182 in SCR3 of DAF. The SERF-negative proband has a substitution mutation that predicts for leucine at this position. SERF has been provisionally assigned the International Society of Blood Transfusion number 021.012 (CROM 12).

show abstract

“…Monoclonal Antibody-Specific Immobilisation of Erythrocyte Antigens This method has been described in more detail elsewhere [17,18]. Briefly, 80 pi of 10% washed red cell suspensions were incubated with 40 pi of mouse monoclonal antibody and 40 pi of human sera for 60 min at 37°C.…”

Section: Absorb Ancementioning

confidence: 99%

Application of the MAIEA Assay to the Kell Blood Group System

Petty¹,

Daniels²,

Tippett³

1994

Vox Sanguinis

Self Cite

View full text Add to dashboard Cite

The monoclonal antibody-specific immobilisation of erythrocyte antigens (MAIEA) test has been employed to investigate the Kell system using five monoclonal antibodies which recognise high frequency epitopes on the 93,000-molecular weight Kell glycoprotein: BRIC 18, BRIC 68, BRIC 107, BRIC 203 and 6-22. BRIC 107, which has anti-k-like (KEL2) specificity, identifies a distinct epitope, whilst competitive binding assays suggested that BRIC 203 (anti-Kp^bc), BRIC 18, BRIC 68 and 6-22 (anti K14) comprise an overlapping set of epitopes. The MAIEA assay has been very successful in confirming the assignment of most of the Kell and para-Kell antigens to the Kell protein. Due to the competitive nature of the assay and the fact that the monoclonal antibodies bind to different regions, the results also suggest the relative positions of some of the Kell antigens on the Kell protein; these appear to be located in at least five spatially distinct regions.

show abstract

Use of the MAIEA Technique to Confirm the Relationship between the Cromer Antigens and Decay‐Accelerating Factor and to Assign Provisionally Antigens to the Short‐Consensus Repeats

Cited by 25 publications

References 19 publications

Application of the MAIEA Assay to the Kell Blood Group System

Application of the MAIEA Assay to the Kell Blood Group System

SERF: a new antigen in the Cromer blood group system

Application of the MAIEA Assay to the Kell Blood Group System

Contact Info

Product

Resources

About